Navigation Links
ImaRx Postpones Release of First Quarter 2008 Financial Results
Date:5/13/2008

Live Webcast and Conference Call Scheduled for Thursday, May 15th at 5 PM

ET

TUCSON, Ariz., May 13 /PRNewswire-FirstCall/ -- ImaRx Therapeutics, Inc. (Nasdaq: IMRX) today announced that the Company has postponed its live webcast and conference call to Thursday, May 15, 2008, at 5:00 p.m. ET to discuss first quarter 2008 financial results; this call was originally scheduled for Tuesday, May 13, 2008, at 5:00 p.m. ET.

The live webcast can be accessed through ImaRx's corporate website at http://www.imarx.com and will be archived on the website for 14 days following the event.

Interested parties may access the conference call by dialing (877) 407-4018 in the U.S. and Canada or (201) 689-8471 internationally. A telephonic replay will be available through May 22, 2008 by dialing (877) 660-6853 in the U.S. and Canada or (201) 612-7415 internationally (Account Number 3055 and Conference ID 284385).

About ImaRx Therapeutics

ImaRx Therapeutics is a biopharmaceutical company developing and commercializing therapies for vascular disorders. The Company's research and development efforts are focused on therapies for stroke and other vascular disorders using its proprietary microbubble technology. The Company's commercialization efforts are currently focused on its product, urokinase, for the treatment of acute massive pulmonary embolism.

Contacts:

The Ruth Group (Investors/Media)

Sara Ephraim/Jason Rando

646-536-7002 or 7025

sephraim@theruthgroup.com

jrando@theruthgroup.com


'/>"/>
SOURCE ImaRx Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. ImaRx Schedules Release of First Quarter 2008 Financial Results
2. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
3. ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase
4. ImaRx Therapeutics Receives Notification from NASDAQ Regarding Non-Compliance with NASDAQs Minimum Bid Price Requirement
5. ImaRx Therapeutics Reports Business Update and Financial Results for Fourth Quarter and Full Year 2007
6. ImaRx Reschedules Release of Corporate Updates and Fourth Quarter and Full Year 2007 Financial Results
7. ImaRx to Report Corporate Updates and 4Q07 Financial Results
8. ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating
9. Chem Rx Corporation Postpones Conference Call to Review Full Year 2007 Financial Results
10. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
11. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today ... a patient who developed lymphedema after being treated for breast cancer benefitted from an ... paradigm for dealing with this debilitating, frequent side effect of cancer treatment. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free validated ... will showcase its product’s latest features from June 26 to June 30, 2016 ... on Disrupting Clinical Trials in The Cloud during the conference. DIA (Drug ...
Breaking Biology Technology:
(Date:3/29/2016)... 29, 2016 LegacyXChange, Inc. (OTC: ... and SelectaDNA/CSI Protect are pleased to announce our successful ... a variety of writing instruments, ensuring athletes signatures against ... collectibles from athletes on LegacyXChange will be assured of ... DNA. Bill Bollander , CEO states, ...
(Date:3/22/2016)... PUNE, India , March 22, 2016 ... new market research report "Electronic Sensors Market for ... Fingerprint, Proximity, & Others), Application (Communication & ... and Geography - Global Forecast to 2022", ... consumer industry is expected to reach USD ...
(Date:3/21/2016)... 2016 Unique technology combines ... superior security   Xura, Inc. ... secure digital communications services, today announced it is working ... enterprise customers, particularly those in the Financial Services Sector, ... authentication within a mobile app, alongside, and in combination ...
Breaking Biology News(10 mins):